Compare Alcon AG (ALC) vs KeyCorp (KEY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs KeyCorp — how do they compare? Alcon AG trades at $66.67 (market cap $32.69B), while KeyCorp trades at $22.63 (market cap $25.22B). The key difference: Alcon AG is the larger of the two by market cap, and KeyCorp pays the higher dividend (3.51%). Which is the better fit depends on your goals.
| ALC | KEY | |
|---|---|---|
Market Cap | $32.69B | $25.22B |
Sector | Health | Financials |
52-Week High | $92.22 | $23.43 |
52-Week Low | $62.02 | $16.78 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 3.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
KeyCorp (KEY) trades at $23.37, up 1.52% today, with a bullish technical signal and strong earnings momentum after three consecutive quarterly beats. The stock shows robust fundamentals with a P/E of 14.37, net income margin of 26.05%, and a new $3 billion buyback program. Recent news highlights its inclusion in dividend-focused strategies and potential for further earnings outperformance.
Outlook remains positive given analyst consensus of $29.55 price target and 60.79% buy ratings. Risks include volatile cash flows and banking sector sensitivity to interest rates, but capital returns and earnings growth support upside potential for investors seeking value and income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
